Search Results - Steven Hager
- Showing 1 - 2 results of 2
-
1
676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M H... by Elizabeth Evans, Nagashree Seetharamu, Crystal Mallow, Maurice Zauderer, Barbara Burtness, Marya Chaney, Alexander Spira, Conor Steuer, Tarek Mekhail, J Thaddeus Beck, Douglas Adkins, Terrence Fisher, Amber Foster, John Leonard, Nabil F Saba, Megan Baumgart, Steven Hager, Christopher Chay
Published in Journal for ImmunoTherapy of Cancer (2023-11-01)Article -
2
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation by Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N. Munster, Yanhong Deng, Gary Richardson, Dong Yan, Myung-Ah Lee, Keun-Wook Lee, Hongming Pan, Steven Hager, Xingya Li, Shaozhong Wei, Xinfang Hou, Craig Underhill, Michael Millward, Ina Nordman, Jingdong Zhang, Jianzhen Shan, Guohong Han, Jaspreet Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Seok Jae Huh, Xiaohua Hu, Yihong Zhang, Ziyong Xiang, Laisheng Luo, Xiaoxi Xie, Zhe Shi, Yaolin Wang, Ling Zhang, Feng Wang, Rui-Hua Xu
Published in Signal Transduction and Targeted Therapy (2025-06-01)Get full text
Article